ReviewEuropean journal of drug metabolism and pharmacokinetics2020
Is Therapeutic Drug Monitoring of Lacosamide Needed in Patients with Seizures and Epilepsy?
Review in European journal of drug metabolism and pharmacokinetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Development and validation of a population pharmacokinetic model for lacosamide in adult patients with epilepsy to inform precision dosing.BMC pharmacology & toxicology · 2026Article
- Placental transfer of third-generation antiepileptic drugs: in vivo lacosamide case study and in vitro investigation of transporter inhibition by lacosamide and perampanel.Journal of pharmaceutical health care and sciences · 2026Article
- Concentration-to-dose ratio as a predictor of lacosamide efficacy in Chinese children with epilepsy: a single-center retrospective cohort study.Frontiers in pharmacology · 2026Article
- PopPK modeling supports BW band dosing of lacosamide for pediatric epilepsy.NPJ genomic medicine · 2025Article
- Pharmacotherapy variability and precision medicine in neurocritical care.Frontiers in neurology · 2025Review
- Influence of age and antiepileptic comedication on lacosamide concentrations in children with epilepsy: A retrospective cohort study.PloS one · 2025Article
- Effects of CYP2C19 and CYP2C9 polymorphisms on the efficacy and plasma concentration of lacosamide in pediatric patients with epilepsy in China.European journal of pediatrics · 2024Article
- Serum perampanel levels in patients with seizures are not affected by hemodialysis.Epilepsia open · 2024Article
- Anti-seizure Medications: Challenges and Opportunities.CNS & neurological disorders drug targets · 2024Review
- Article
- Lacosamide Intoxication-induced Wide QRS Tachycardia Successfully Treated with Veno-arterial Extracorporeal Membrane Oxygenation.Internal medicine (Tokyo, Japan) · 2023Article
- Editorial: Therapeutic drug monitoring (TDM): a useful tool for pediatric pharmacology applied to routine clinical practice, Volume II.Frontiers in pharmacology · 2023Article
- Therapeutic drug monitoring of lacosamide among children: is it helpful?Frontiers in pharmacology · 2023Article
- Plasma lacosamide monitoring in children with epilepsy: Focus on reference therapeutic range and influencing factors.Frontiers in pediatrics · 2022Article
- Lacosamide-induced sinus node dysfunction followed by severe agranulocytosis.BMC neurology · 2021Article
- Feasibility of Using Oral Fluid for Therapeutic Drug Monitoring of Antiepileptic Drugs.European journal of drug metabolism and pharmacokinetics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lacosamide is an antiepileptic drug (AED) that has linear pharmacokinetics, predictable blood concentrations, and few drug interactions, setting it apart from other AEDs that require vigorous therapeutic drug monitoring (TDM) such as phenytoin and carbamazepine. However, there have been reports of altered lacosamide pharmacokinetics in some populations. The purpose of this review is to determine whether lacosamide pharmacokinetics are altered in certain patient populations, suggesting the need for TDM. A literature search of Medline, Scopus, Embase, and Cochrane trials was conducted on January 3, 2019 (and then updated on September 2, 2019) to search for articles relevant to the TDM or pharmacokinetics of lacosamide. A total of 56 relevant articles were found and included in this review. Dose of lacosamide is linearly correlated with plasma concentrations and efficacy. However, currently there is no well-established reference range. Overall, the recommended reference ranges varied from 2.2 to 20 mg/L. Lacosamide has very few clinically relevant drug-drug interactions; however, there seems to be a significant drug interaction between lacosamide and enzyme-inducer AEDs. Based on available literature, it appears that lacosamide pharmacokinetics may be altered in severe renal dysfunction, in patients on dialysis and with extremes of age. More evidence is currently needed on lacosamide pharmacokinetics in pregnancy and critical illness. While it is not practical to utilize TDM for all patients, TDM may be useful in patients taking enzyme-inducer AEDs, in patients with decreased renal function or on dialysis, and older adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.